GREG YAP CHIEF EXECUTIVE OFFICER AND CO-FOUNDER
Greg co-founded Biodesy, Inc., and now serves as CEO. He is an entrepreneurial leader and general manager who specializes in building rapidly growing companies in dynamic markets. His background includes small, medium, and large businesses focused on cutting edge research tools, translational medicine, and medical diagnostics. Greg was most recently the first-ever healthcare Entrepreneur in Residence at GE, where he was responsible for strategic business assessment and planning for novel GE technology. Previously, Greg was Lifecycle Leader, Advanced Staining Assays, at Ventana Medical Systems, a member of the Roche Group, where he led Ventana’s market-leading ~$500M cancer diagnostic assay business. These products, ranging from standard-of-care tests for all major cancers to novel proprietary assays and companion diagnostics, are used to guide treatment for nearly half of all cancer patients worldwide. Greg was also Chief Operating Officer of CELLective Dx, a venture-backed startup developing an innovative platform for analyzing circulating tumor cells, and held general management roles at Affymetrix, the pioneer of DNA microarrays, including VP Molecular Diagnostics and VP DNA Products, where he started and grew the genetics business from zero to ~$100 million in revenue. Greg has also worked in venture capital with Bay City Capital and in management consulting with McKinsey & Company. He is a member of the boards of directors of Outward Bound California and the national Outward Bound Services Group. Greg received his MBA from Stanford University and his AB in molecular biology, summa cum laude, from Princeton University.